KP 09S
Alternative Names: KP-09SLatest Information Update: 29 Sep 2023
At a glance
- Originator Kangpu Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Aug 2023 Preclinical trials in Cancer in China (unspecified route), before August 2023 (Kangpu Biopharmaceutical pipeline, August 2023)